Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

Chandra Belani, Jose R. Pereira, Joachim von Pawel, Anna Pluzanska, Vera Gorbounova, Eckhard Kaukel, Karin V. Mattson, Rodryg Ramlau, Aleksandra Szczesna, Panos Fidias, Michael Millward, Frank Fossella

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalLung Cancer
Volume53
Issue number2
DOIs
StatePublished - Aug 1 2006

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Randomized Controlled Trials
Quality of Life
Drug Therapy
Cisplatin
Lung Neoplasms
Platinum
Pain
Carboplatin
Weight Loss

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Belani, Chandra ; Pereira, Jose R. ; von Pawel, Joachim ; Pluzanska, Anna ; Gorbounova, Vera ; Kaukel, Eckhard ; Mattson, Karin V. ; Ramlau, Rodryg ; Szczesna, Aleksandra ; Fidias, Panos ; Millward, Michael ; Fossella, Frank. / Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. In: Lung Cancer. 2006 ; Vol. 53, No. 2. pp. 231-239.
@article{8a07b4e3e6544a1cb9ccec18d85a39aa,
title = "Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial",
abstract = "Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-na{\"i}ve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item {"}QoL today{"}: P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item {"}health state today{"}: P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS {"}QoL today{"}, which was not significant.",
author = "Chandra Belani and Pereira, {Jose R.} and {von Pawel}, Joachim and Anna Pluzanska and Vera Gorbounova and Eckhard Kaukel and Mattson, {Karin V.} and Rodryg Ramlau and Aleksandra Szczesna and Panos Fidias and Michael Millward and Frank Fossella",
year = "2006",
month = "8",
day = "1",
doi = "10.1016/j.lungcan.2006.05.003",
language = "English (US)",
volume = "53",
pages = "231--239",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Belani, C, Pereira, JR, von Pawel, J, Pluzanska, A, Gorbounova, V, Kaukel, E, Mattson, KV, Ramlau, R, Szczesna, A, Fidias, P, Millward, M & Fossella, F 2006, 'Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial', Lung Cancer, vol. 53, no. 2, pp. 231-239. https://doi.org/10.1016/j.lungcan.2006.05.003

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. / Belani, Chandra; Pereira, Jose R.; von Pawel, Joachim; Pluzanska, Anna; Gorbounova, Vera; Kaukel, Eckhard; Mattson, Karin V.; Ramlau, Rodryg; Szczesna, Aleksandra; Fidias, Panos; Millward, Michael; Fossella, Frank.

In: Lung Cancer, Vol. 53, No. 2, 01.08.2006, p. 231-239.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

AU - Belani, Chandra

AU - Pereira, Jose R.

AU - von Pawel, Joachim

AU - Pluzanska, Anna

AU - Gorbounova, Vera

AU - Kaukel, Eckhard

AU - Mattson, Karin V.

AU - Ramlau, Rodryg

AU - Szczesna, Aleksandra

AU - Fidias, Panos

AU - Millward, Michael

AU - Fossella, Frank

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

AB - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

UR - http://www.scopus.com/inward/record.url?scp=33745893529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745893529&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.05.003

DO - 10.1016/j.lungcan.2006.05.003

M3 - Article

C2 - 16787687

AN - SCOPUS:33745893529

VL - 53

SP - 231

EP - 239

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -